Five Prime Therapeutics Inc (FPRX) : Hays Advisory added new position in Five Prime Therapeutics Inc during the most recent quarter end. The investment management firm now holds 135,722 shares of Five Prime Therapeutics Inc which is valued at $6,392,506 , the company said in a statement filed on Jul 19, 2016 with the SEC.Five Prime Therapeutics Inc makes up approximately 0.97% of Hays Advisory’s portfolio.
Other Hedge Funds, Including , Acadian Asset Management boosted its stake in FPRX in the latest quarter, The investment management firm added 578,411 additional shares and now holds a total of 1,094,368 shares of Five Prime Therapeutics Inc which is valued at $51,544,733. Five Prime Therapeutics Inc makes up approx 0.25% of Acadian Asset Management’s portfolio. Fox Run Management L.l.c. added FPRX to its portfolio by purchasing 10,800 company shares during the most recent quarter which is valued at $508,680. Five Prime Therapeutics Inc makes up approx 0.24% of Fox Run Management L.l.c.’s portfolio. Simplex Trading added FPRX to its portfolio by purchasing 660 company shares during the most recent quarter which is valued at $31,086. Nisa Investment Advisors added FPRX to its portfolio by purchasing 500 company shares during the most recent quarter which is valued at $22,860.Creative Planning reduced its stake in FPRX by selling 425 shares or 8.02% in the most recent quarter. The Hedge Fund company now holds 4,872 shares of FPRX which is valued at $208,181.
Five Prime Therapeutics Inc opened for trading at $45.33 and hit $47.46 on the upside on Wednesday, eventually ending the session at $47.1, with a gain of 4.90% or 2.2 points. The heightened volatility saw the trading volume jump to 5,45,768 shares. Company has a market cap of $1,328 M.
On the company’s financial health, Five Prime Therapeutics Inc reported $-0.49 EPS for the quarter, beating the analyst consensus estimate by $ 0.30 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.79. The company had revenue of $6.50 million for the quarter, compared to analysts expectations of $6.22 million. The company’s revenue was up 51.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.
Five Prime Therapeutics Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include FPA008 FPA144 and FP-1039/GSK3052230. FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1) receptor (CSF1R) that the Company is developing in rheumatoid arthritis. FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b) which the Company is developing to treat patients with gastric cancer. FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation. Its partner GlaxoSmithKline is developing FP-1039/GSK3052230 to treat patients with squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.